Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America. The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as structured reports designed to support clinical decision-making for various diseases, including depression, anxiety, ADHD, PTSD, MCI, dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, ASD, and traumatic brain injury. It serves clinicians. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York.…
Firefly Neuroscience Reports 373% Year-Over-Year Increase in U18 ADHD Evoke™ Scans as Commercial Expansion Accelerates
The Small Cap Showcase Highlights 8 Public Companies at Their Investor Conference Today
Firefly Neuroscience (NASDAQ: AIFF) is listed on Nasdaq, where its shares trade in USD. It belongs to the Software - Application industry, part of the Technology sector, and reports about 17 employees.
The shares were at 0.7500 USD on 20 November 2026, down 52.8% over 52 weeks. Its 52-week range is 0.6200 USD to 3.150 USD: the price is 76.2% below the high and 21.0% above the low.
Its market capitalisation is 11.81M USD.
Firefly Neuroscience reports return on equity of -260.3%, an operating margin of -382.8% and revenue up 66.8% year over year.
It holds more cash than debt, a net cash position of 8.02M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.
No upcoming events tracked.